Deciphering the Possible Role of Statins as Antibacterial Agents through Molecular Modelling Approach Role of statins as antibacterial agents
Iranian Journal of Pharmaceutical Sciences,
Vol. 17 No. 2 (2021),
1 April 2021
,
Page 67-86
https://doi.org/10.22037/ijps.v17.40287
Abstract
The global incidence of resistance to commonly used antibiotics was a challenging public health concern that justifies the urgency in developing novel antibacterial agents. ATP-dependent Mur ligases (MurC, MurD, MurE, and MurF) are validated targets in antibacterial drug design. Drug repurposing or drug repositioning is an alternative strategy in identifying new indications for the currently approved drugs. Statins are currently FDA-approved drugs used to treat hyperlipidemia. The pleiotropic effects of statins, along with their anticipated antibacterial properties, encouraged us to investigate them against MurD ligase of Escherichia coli and Staphylococcus aureus. The molecular docking and MMGB-SA studies revealed that amongst all selected statins, pravastatin exhibited higher binding affinity with the catalytic residues of Escherichia coli (-7.24 kcal/mol and -88.36 kcal/mol) and Staphylococcus aureus (-7.47 kcal/mol and -63.75 kcal/mol) MurD ligases. Further, 20 ns MD simulation showed stability and favorable interaction pattern of pravastatin with both enzymes.
- Escherichia coli
- MMGB-SA
- Molecular dynamics
- MurD ligase
- Statins
- Staphylococcus aureus
How to Cite
References
[2] El Zoeiby A, Sanschagrin F, Levesque RC. Structure and function of the Mur enzymes: development of novel inhibitors. Mol. Microbiol. (2003) 47 (1): 1-12.
[3] Auger G, van Heijenoort J, Blanot D. Synthesis of N-Acetylmuramic acid derivatives as potential inhibitors of the D-glutamic acid-adding enzyme. J. Prakt. Chem. (1995) 337 (1): 351-57.
[4] Sova M, Kovac A, Turk S, Hrast M, Blanot D, Gobec S. Phosphorylated hydroxylethyl-amines as novel inhibitors of the bacterial cell wall biosynthesis enzymes MurC to MurF. Bioorg. Chem. (2009) 37 (6): 217-22.
[5] Kotnik M, Humljan J, Contreras-Martel C, Oblak M, Kristan K, Herve M, et al. Structural and functional characterization of enantiomeric glutamic acid derivatives as potential transition state analog inhibitors of MurD ligase. J. Mol. Biol. (2007) 370 (1): 107-15.
[6] Humljan J, Kotnik J, Contreras-Martel C, Blanot D, Urleb U, Dessen A, et al. Novel naphthalene-N-sulfonyl-D-glutamic acid derivatives as inhibitors of MurD, a key peptidoglycan biosynthesis enzyme. J. Med. Chem. (2008) 51 (23): 7486-94.
[7] Tomasic T, Zidar N, Kovac A, Turk S, Simcic M, Blanot D, et al. 5- Benzylidene thiazolidin-4-ones as Multi-target Inhibitors of Bacterial Mur Ligases. Chem. Med. Chem. (2010) 5 (2): 286-95.
[8] Tomasic T, Sink R, Zidar N, Fic A, Contreras-Martel C, Dessen A, et al. Dual Inhibitor of MurD and MurE Ligases from Escherichia coli and Staphylococcus aureus. ACS Med. Chem. Lett. (2012) 3 (8): 626-30.
[9] Perdih A, Kovac A, Wolber G, Blanot D, Gobec S, Solmajer T. Discovery of novel benzene 1, 3-dicarboxylic acid inhibitors of bacterial MurD and MurE ligases by structure-based virtual screening approach. Bioorg. Med. Chem. Lett. (2009) 19 (10): 2668-73.
[10] Zidar N, Tomasic T, Sink R, Kovac A, Patin D, Blanot D, et al. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. Eur. J. Med. Chem. (2011) 46 (11): 5512-23.
[11] Perdih A, Hrast M, Pureber K, Barreteau H, Grdadolnik SG, Kocjan D, et al. Furan-based benzene mono- and dicarboxylic acid derivatives as multiple inhibitors of the bacterial Mur ligases (MurC–MurF): experimental and computational characterization. J. Comput. Aided. Mol. Des. (2015) 29 (6): 541-60.
[12] Azam MA, Jupudi S. Structure-based virtual screening to identify inhibitors against Staphylococcus aureus MurD enzyme. Struct. Chem. (2019) 30: 2123-33.
[13] Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages. Arterioscler. Thromb. Vasc. Biol. (1998) 18 (11): 1671-78.
[14] Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, et al. Comparative Effects of Statin and Fibrate on Nitric Oxide Bioactivity and Matrix Metalloproteinase in Hyperlipidemia. Int. J. Cardiol. (2004) 97 (2): 239-44.
[15] Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. Circulation (1998) 97 (12): 1129-35.
[16] Liao JK, Laufs U. Pleiotropic Effects of Statins. Annu. Rev. Pharmacol. Toxicol. (2005) 45: 89-118.
[17] Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke Protection by 3-Hydroxy-3-Methylglutaryl (HMG)-CoA Reductase Inhibitors Mediated by Endothelial Nitric Oxide Synthase. Proc. Natl. Acad. Sci. (1998) 95 (15): 8880-85.
[18] Pickup JC. Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care (2004) 27 (3): 813-23.
[19] Hennessy E, O Callaghan J, Mooij MJ, Legendre C, Camacho-Vanegas O, Camacho SC, et al. The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection. PLoS One (2014) 9: e102200.
[20] Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome. Biol. (2004) 5 (11): 248.
[21] Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug. Discov. (2005) 4 (12): 977-87.
[22] Guerra-De-Blas PDC, Torres-Gonzalez P, Bobadilla-Del-Valle M , Sada-Ovalle I , Ponce-De-Leon-Garduno A, Sifuentes-Osornio J. Potential Effect of Statins on Mycobacterium tuberculosis Infection. J. Immunol. Res. (2018) 2018: 7617023.
[23] Kaminska M, Aliko A, Hellvard A, Marczyk A, Mydel P. Effects of statins on multispecies oral biofilm. J. Oral. Microbiol. (2017) 9 (sup1): 1325249.
[24] Graziano TS, Cuzzullin MC, Franco GC, Schwartz-Filho HO, de Andrade ED, Groppo FC et al. Statins and antimicrobial effects: Simvastatin as a potential drug against Staphylococcus aureus biofilm. PloS One. (2015) 10 (5): e0128098.
[25] Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother. (2008) 61(2): 362-64.
[26] Masadeh M, Mhaidat N, Alzoubi K, Al-azzam S, Alnasser Z. Antibacterial Activity of Statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann. Clin. Microbiol. Antimicrob. (2012) 11: 13.
[27] Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. (2014) 209 (5): 754-63.
[28] Thangamani S, Mohammad H, Abushahba MFN, Hamed MI, Sobreira TJP, Hedrick VE, et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci. Rep. (2015) 5: 16407.
[29] Skerry C, Pinn MLO, Bruiners N, Pine R, Gennaro ML, Karakousis PC. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. (2014) 69 (9): 2453-57.
[30] Lobato LS, Rosa P S, Ferreira J S, Neumann Ada S, da Silva M G, do Nascimento D C, et al. Statins increase rifampin mycobactericidal effect. Antimicrob. Agents. Chemother. (2014) 58 (10): 5766-74.
[31] Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J. Antimicrob. Chemother. (2016) 71(6): 1570-77.
[32] Gupta M, Kumar A. Comparison of Minimum Inhibitory Concentration (MIC) Value of Statin Drugs: A Systematic Review. Anti-Infective Agents. (2019) 17 (1): 4-19.
[33] Eljaaly K, Alshehri S. An updated review of interactions of statins with antibacterial and antifungal agents. J. Transl. Sci. (2017) 3 (3): 1-4.
[34] Azam MA, Jupudi S. Extra precision docking, free energy calculation and molecular dynamics studies on glutamic acid derivatives as MurD inhibitors. Comput. Biol. Chem. (2017) 69: 55-63.
[35] Azam MA, Jupudi S, Saha N, Paul RK. Combining molecular docking and molecular dynamics studies for modelling Staphylococcus aureus MurD inhibitory activity. SAR. QSAR. Environ. Res. (2019) 30 (1): 1-20.
[36] Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, et al. OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. J. Chem. Theory. Comput. (2019) 15 (3): 1863-74.
[37] Jorgensen WJ, Madura JD. Temperature and size dependnce for Monte Carlo simulations of TIP4P water. Mol. Phys. (1985) 56 (6): 1381-92
[38] Lawrence CP, Skinner JL. Flexible TIP4P model for moleculardynamics simulation of liquid water. Chem. Phys. Lett. (2003) 372 (5-6): 842- 47.
[39] Essmann U, Perera L, Berkowit ML, Darden T, Lee H , Pedersen LG. A smooth particle mesh Ewald method. J. Chem. Phys. (1995) 103 (19): 8577-93.
- Abstract Viewed: 76 times
- IJPS_Volume 17_Issue 2_Pages 67-86 Downloaded: 39 times